Przejdź do zawartości
Merck

The canonical smooth muscle cell marker TAGLN is present in endothelial cells and is involved in angiogenesis.

Journal of cell science (2021-08-03)
Kiyomi Tsuji-Tamura, Saori Morino-Koga, Shingo Suzuki, Minetaro Ogawa
ABSTRAKT

Elongation of vascular endothelial cells (ECs) is an important process in angiogenesis; however, the molecular mechanisms remain unknown. The actin-crosslinking protein TAGLN (transgelin, also known as SM22 or SM22α) is abundantly expressed in smooth muscle cells (SMCs) and is widely used as a canonical marker for this cell type. In the course of studies using mouse embryonic stem cells (ESCs) carrying an Tagln promoter-driven fluorescence marker, we noticed activation of the Tagln promoter during EC elongation. Tagln promoter activation co-occurred with EC elongation in response to vascular endothelial growth factor A (VEGF-A). Inhibition of phosphoinositide 3-kinase (PI3K)-Akt signaling and mTORC1 also induced EC elongation and Tagln promoter activation. Human umbilical vein endothelial cells (HUVECs) elongated, activated the TAGLN promoter and increased TAGLN transcripts in an angiogenesis model. Genetic disruption of TAGLN augmented angiogenic behaviors of HUVECs, as did the disruption of TAGLN2 and TAGLN3 genes. Tagln expression was found in ECs in mouse embryos. Our results identify TAGLN as a putative regulator of angiogenesis whose expression is activated in elongating ECs. This finding provides insight into the cytoskeletal regulation of EC elongation and an improved understanding of the molecular mechanisms underlying the regulation of angiogenesis.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-TAGLN antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
Roche
cOmplete, Mini Protease Inhibitor Cocktail, Tablets provided in EASYpacks
Sigma-Aldrich
Monoclonal Anti-Actin, α-Smooth Muscle, clone 1A4, ascites fluid
Sigma-Aldrich
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2, Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2, CAS 612847-09-3, is a cell-permeable, reversible inhibitor of Akt1/Akt2 (IC₅₀ = 58 nM, 210 nM, & 2.12 µM for Akt1, Akt2, and Akt3, respectively).